|
|
|
|
|
|
|
M Tue W Th F |
|
6 October, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AstraZeneca just spent $1 billion on a new 10-story building in Cambridge, MA — wedged between Thermo Fisher, Biogen and Akamai — helping to redefine the neighborhood’s skyline. At its grand opening on Monday, AstraZeneca showed off its new digs, including a conceptual map of the nearby Charles River on the second-floor ceiling, its whiz-bang new technology and its 3D talking hologram, Priya, who responded to reporters’ questions, but only with answers readily available online. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
A dark-money-style group pushing drug pricing reform funded new Harvard research and a Trump pollster's survey — but won't say who pays for it. |
|
|
|
by Max Bayer
|
What do the Seattle Latino Chamber of Commerce, the Venezuelan-American Republican Club of Miami-Dade and the lower-tier professional men’s soccer team Akron City Football Club... | |
|
|
|
|
|
|
by Karen Weintraub
|
AstraZeneca prides itself on investing roughly a quarter of its annual revenue into research and development. On Monday, the company inaugurated a 570,000-square-foot building in... | |
|
|
|
|
|
|
by Lei Lei Wu
|
ArriVent BioPharma, an early adopter of the China licensing model, reported that its lead lung cancer drug failed a Phase 3 trial. Firmonertinib, an EGFR... | |
|
|
|
|
|
|
by Ayisha Sharma
|
AbbVie and Genmab said their T-cell engager Epkinly passed a late-stage trial in first-line diffuse large B-cell lymphoma, clearing the way for a potential market... | |
|
|
|
|
|
|
|
|
|
Worldwide made. Thanks for reading.
|
|
|
|
|
|
|
|
